Suven Life Sciences announced that it secured three product patents- one product patent from Australia, two product patents from Japan and one product patent from Hong Kong corresponding to the new chemical entity for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of nineteen granted patents from Australia, fourteen granted patents from Japan and fifteen granted patents from Hong Kong. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for Major Depressive Disorder (MDD) with high unmet medical need with huge market potential globally," said Venkat Jasti, chief executive officer of Suven.
Shares of the company gained Rs 12.45, or 6%, to trade at Rs 220.10 at the BSE (10.58 am., Monday).